AGIO vs EW · rev $36.5M vs P/E 47, rev $1.39B
Agios Pharm (AGIO) versus Edwards Lifesciences Corp (EW) — a side-by-side from cached financials, not a winner call.
Agios Pharm (AGIO) is a biotechnology company listed on US.
Edwards Lifesciences Corp (EW) is a medical devices company listed on NYSE.
Latest reported AGIO revenue for 2024-12-31 was $36.5M. Net income was $673.7M. Revenue was up 36.1% from 2023-12-31 to 2024-12-31. AGIO currently screens at market cap $1.68B.
Latest reported EW revenue for 2024-12-31 was $1.39B. Net income was $385.6M. Revenue was up 2.3% from 2024-09-30 to 2024-12-31. EW currently screens at market cap $49.91B and trailing P/E 46.9.
AGIO currently screens at market cap $1.68B. EW currently screens at market cap $49.91B and trailing P/E 46.9.
Not investment advice. Open the AGIO and EW stock pages for the full models.
Not investment advice.